Not Yet Recruiting
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
NCT05778149
- Conditions
- Anlotinib, Aumolertinib, EGFR Activating Mutation, +2 more
- Locations
-
Not specified